Similarly, at baseline, average weekly sublingual nitroglycerin use was similar between treatment arms (4.1 [3.7-4.6] versus 4.5 [4.1-5.0]; ratio 0.92 [0.80-1.06]). During weeks 2-8, the average weekly number of sublingual nitroglycerin doses was significantly lower in patients receiving ranolazine compared to placebo (1.7 [1.6-1.9] versus 2.1 [1.9-2.3] doses; ratio 0.83 [0.73-0.94] P=0.003).In prespecified subgroup analyses, the efficacy of ranolazine was consistent irrespective of baseline average weekly angina episodes (<3 versus ≥3), number of concomitant antianginal medications (one versus two), age (<65 versus ≥65) and sex. There was, however, a significant difference in the effect of ranolazine versus placebo on the primary endpoint by the geographic region of enrollment (Russia, Ukraine and Belarus versus other countries; P interaction=0.016): The average number of weekly angina episodes between the ranolazine and placebo arms among patients enrolled in Russia, Ukraine and Belarus was not statistically significantly different (4.1 [3.9-4.4] versus 4.3 [4.1-4.6]; ratio 0.95 [0.87-1.05] P=0.31). Among patients enrolled in other countries, there was a significant reduction in average weekly angina episodes in the ranolazine group versus placebo (3.1 [2.8-3.5] versus 4.1 [3.7-4.6]; ratio 0.77 [0.65-0.90] P=0.002).
Gilead’s Ranexa® Reduces Angina Frequency In Study Of Chronic Angina Patients With Type 2 Diabetes
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.